Bone Biologics

Advancing bone regeneration with our proprietary NELL-1 platform. Focused on improving outcomes in spine fusion and orthopedic care.

NASDAQ: $BBLG

[Bone Biologics @BoneBiologics]

Six Australian sites have agreed to participate in $BBLG’s first-in-human pilot clinical trial of NB1. The expanded network is expected to accelerate patient screening & surgical scheduling, supporting $BBLG's goal of completing enrollment by year-end.

🔗 https://t.co/cjklDfl2Zj

[Bone Biologics @BoneBiologics]

In a new interview on Progress, Potential, and Possibilities, $BBLG's CEO, Jeffrey Frelick, discusses how targeted NELL-1 technology is designed to teach the body where to build bone for safer, more predictable spinal fusion.

🔗: https://t.co/qolV1CU1Hk

#Orthobiologics

[Bone Biologics @BoneBiologics]

$BBLG to participate in the @HCWCO Global Investment Conference, Sept 14–16. CEO Jeff Frelick will hold 1-on-1 investor meetings with a virtual presentation available starting Sept 11 at 7 AM ET.

Learn more here: https://t.co/H50Hare9u2

[Bone Biologics @BoneBiologics]

With a large market opportunity, proprietary technology platform, encouraging preclinical results, and a defined FDA regulatory pathway, $BBLG remains focused on developing next-generation #orthobiologics solutions.

Learn about our platform: https://t.co/2sIMhsNze8

[Bone Biologics @BoneBiologics]

In a recent interview with Bio Pharma Boardroom, $BBLG’s CEO, Jeffrey Frelick, discusses how NELL-1 is designed to help “hard healers” achieve safer, more reliable bone regeneration.

🔗: https://t.co/PoLrkdts9G

[Bone Biologics @BoneBiologics]

New coverage from @orthothisweek featured $BBLG's approach to advancing spinal fusion with NB1, highlighting the Company's targeted NELL-1 technology, clinical development program, and strategy to support bone regeneration.

Read more: https://t.co/zUpKmcHBTQ

#Orthobiologics

[Bone Biologics @BoneBiologics]

$BBLG announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, building on the 29-month milestone reached in May 2026.

The milestone is expected to support greater manufacturing and supply-chain flexibility.

🔗: https://t.co/uZ3Ot0dio2

[Bone Biologics @BoneBiologics]

$BBLG's CEO Jeffrey Frelick was featured in a new Drug Delivery Leader article on the future of orthobiologics & targeted bone regeneration.

The feature explores the potential of next-generation recombinant therapies to advance bone healing.

Read more: https://t.co/dn8FtfvORq

[Bone Biologics @BoneBiologics]

$BBLG continues to execute on its 2026 development priorities, advancing the NB1 clinical program while strengthening manufacturing readiness, capital planning and IP initiatives.

Learn more: https://t.co/yOnjQRkCdr

[Zacks SCR @ZacksSmallCap]

$BBLG @BoneBiologics Secures Financing for Critical Trials https://t.co/MRYfQC1ync

[Bone Biologics @BoneBiologics]

$BBLG issued a mid-year shareholder update highlighting progress across its 2026 priorities.

Highlights include an operating runway through Q2 2027, continued #NB1 clinical advancement, and a 29-month validated shelf life for rhNELL-1.

🔗https://t.co/yOnjQRkCdr

[Bone Biologics @BoneBiologics]

$BBLG's President & CEO, Jeffrey Frelick, discusses how regenerative medicine is changing the way researchers and clinicians think about spinal fusion and bone repair in an article with @LifeScienceDN.

Read more: https://t.co/dWbOnHn7YQ

[Life Science Daily News @LifeScienceDN]

Could biologics replace spinal hardware? Jeffrey Frelick of Bone Biologics on how regenerative medicine is reshaping spine fusion. https://t.co/NCoIRT7bAd #RegenerativeMedicine #SpineFusion

[Bone Biologics @BoneBiologics]

$BBLG has entered into a definitive agreement with a single healthcare-focused institutional investor for $3.0 million upfront with up to ~ $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash.

🔗 https://t.co/SYvgfVWy8g

@HCWCO

[Bone Biologics @BoneBiologics]

$BBLG's CEO, Jeffrey Frelick, spoke with @timsandle of @digitaljournal about the Company's differentiated approach to bone regeneration, the potential of NB-1 and NELL-1 in spinal fusion, and ongoing clinical development efforts.

Read more: https://t.co/hxW0l5TyC4

[Bone Biologics @BoneBiologics]

Today on #InternationalBiotechDay, we’re celebrating the innovation driving the future of healthcare and regenerative medicine.

Biotechnology continues to advance new approaches designed to support bone healing and regeneration for patients in need.

$BBLG

[Bone Biologics @BoneBiologics]

$BBLG's mission is to harness the potential of NELL-1 to advance bone regeneration and improve outcomes across spinal fusion and other bone-related procedures.

Read more: https://t.co/ix1RWk1uqI

[Bone Biologics @BoneBiologics]

This #ClinicalTrialsDay, $BBLG recognizes the patients, investigators, clinicians, and researchers advancing clinical research.

#BBLG continues advancing its proprietary NELL-1 platform and NB1 bone graft device in a pilot clinical study for lumbar spinal fusion.

#CTD2026

[Bone Biologics @BoneBiologics]

$BBLG announces the validated shelf life of its rhNELL-1 protein product has been extended to 29 months, supported by continued third-party stability data.

The milestone advances manufacturing readiness ahead of a future pivotal study.

Read more: https://t.co/opT518smcF

[Bone Biologics @BoneBiologics]

$BBLG's proprietary NELL-1 platform is being developed to address orthobiologics industry challenges by benefitting patients through faster healing, better outcomes, & to benefit the healthcare system through less surgical time & lower costs.

Learn more: https://t.co/ix1RWk1uqI

[Bone Biologics @BoneBiologics]

$BBLG is advancing bone regeneration through its proprietary NELL-1 platform, a recombinant protein designed to promote targeted, controlled bone formation and provide targeted bone regeneration for “hard healers” with an advantageous safety profile.

https://t.co/fSCW4t5oXA